Houston Methodist Cytopathology and Small Biopsy Update 2023
$30.00
9 videos + 1 pdf, size: 6.47 GB
Description
+ Information:
Physicians and cytologists need the most up to date knowledge and strategies in pathology and cytopathology in order to provide the most appropriate ancillary testing for their patients and for guiding patient management. With the current update, attendees will learn the various new evidence-based reporting terminologies or updates to previously existing ones..
This will enable them to assess the patient’s risk of malignancy specifically regarding findings in thyroid, respiratory, urinary, body fluid, and pancreatobiliary cytology and small biopsies. By understanding these new site-specific reporting systems, attendees will know the risk of malignancy associated with each reporting category and appropriate ancillary testing; and therefore better guide management of their patients The World Health Organization under the guidance of the International Academy of Cytology and other organizations is currently in the process of publishing cytopathology reporting terminology.
An update/status on these will be provided. Additionally, digital pathology and other new technologies, as they apply specifically to cytology and small specimens, will be discussed. New developments in the field that will impact patient care in the future will also be presented.
This course design for physicians, residents and fellows, cytopathologists, cytotechnologists, pathologists, residents and fellows in pathology, ENT, endocrinology, urology and internal medicine.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the diagnosis molecular testing and management of thyroid nodules and update to the Thyroid Bethesda System Reporting Terminology.
- Understand how the risk of malignancy in reporting terminology is affected by the inclusion of non-invasive follicular thyroid neoplasm with papillary like features (NIFTP).
- Understand respiratory, pancreatobiliary, urinary and body fluid cytology reporting terminology, risk of malignancy associated with the various reporting categories, and new ancillary testing options
- Apply appropriate molecular testing to small specimens for management of lesions of lung, pancreaticobiliary, urinary tract and other systems
- Participants should be able to define risk stratification based on cytology and HPV testing in gynecologic cytology
- Be current on the role of HPV testing in head and neck cancer and Lower anogenital tract reporting terminology
+ Topics:
- Agenda.pdf
Computational Cytology- Past, Present and Future.mp4
Diagnostic and Ancillary Testing of Pulmonary Cytopathology and Small Biopsy Specimens.mp4
HPV Testing in Gynecologic Cytology and Primary HPV Screening. Current Status and Future Directions.mp4
Innovative Next Generation Cytology Imaging and Implications for our Practice.mp4
Overview of the Revised 3rd Edition Bethesda System for Reporting Thyroid Cytopathology.mp4
Paris 2.0 Highlights and Updates in Urinary Cytology.mp4
Update on HPV Testing in Head and Neck Cancer.mp4
Update on Other Cytology Reporting Terminologies (Body fluids, Salivary, WHO on Musculoskeletal, Lymph nodes).mp4
WHO System for Reporting Pancreaticobiliary Cytology An Overview.mp4
